Altss Research / Venture case 33
Theranos
Theranos dissolved in September 2018 after achieving a reported $9 billion private funding valuation in 2014. Its assets were assigned for the benefit of creditors.
Altss Research · Evidence reviewed · Historical event record
Historical private valuation
$9bnTIME reported a $9 billion company valuation in a 2014 private funding round. Month and pre-money versus post-money basis are not specified in that report.
Wind-down
No sale priceDissolution and creditor assignment. The District of Arizona’s March 2020 order states that Theranos dissolved in September 2018 and assigned its assets to Theranos, LLC for creditors’ benefit. This was an assignment, not a reported acquisition price.
These figures have different valuation bases and dates. Their difference is not a measure of investor losses. Methodology ↗
The documented timeline
Private funding valuation
Contemporary reporting identifies a $9 billion funding-round valuation during 2014.
Dissolution
The company dissolved and assigned assets for creditors’ benefit, as recorded in the court order.
Source documents
Publication and access dates identify the evidence used for this case.
TIME · Financial reporting · Published Apr 18, 2016 · Accessed Oct 26, 2026
U.S. District Court, District of Arizona · Primary source · Published Mar 6, 2020 · Accessed Oct 26, 2026
Logo: Theranos logo source. Company trademark rights remain.
